Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
21
10
2019
revised:
17
01
2020
accepted:
24
03
2020
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
epublish
Résumé
The American Joint Committee on Cancer staging and other prognostic tools fail to account for stage-independent variability in outcome. We developed a prognostic classifier adding Immunoscore to clinicopathological and molecular features in patients with stage III colon cancer. Patient (n = 559) data from the FOLFOX arm of adjuvant trial NCCTG N0147 were used to construct Cox models for predicting disease-free survival (DFS). Variables included age, sex, T stage, positive lymph nodes (+LNs), N stage, performance status, histologic grade, sidedness, Poorer DFS was found for tumors that were T4 vs T3 (hazard ratio [HR] = 1.76, 95% confidence interval [CI] = 1.19 to 2.60; The Immunoscore can enhance the accuracy of survival prediction among patients with stage III colon cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The American Joint Committee on Cancer staging and other prognostic tools fail to account for stage-independent variability in outcome. We developed a prognostic classifier adding Immunoscore to clinicopathological and molecular features in patients with stage III colon cancer.
METHODS
METHODS
Patient (n = 559) data from the FOLFOX arm of adjuvant trial NCCTG N0147 were used to construct Cox models for predicting disease-free survival (DFS). Variables included age, sex, T stage, positive lymph nodes (+LNs), N stage, performance status, histologic grade, sidedness,
RESULTS
RESULTS
Poorer DFS was found for tumors that were T4 vs T3 (hazard ratio [HR] = 1.76, 95% confidence interval [CI] = 1.19 to 2.60;
CONCLUSIONS
CONCLUSIONS
The Immunoscore can enhance the accuracy of survival prediction among patients with stage III colon cancer.
Identifiants
pubmed: 32455336
doi: 10.1093/jncics/pkaa023
pii: pkaa023
pmc: PMC7236783
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkaa023Subventions
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180835
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210509
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA114740
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Hum Pathol. 2004 Jul;35(7):808-16
pubmed: 15257543
Eur J Cancer. 2011 May;47(7):990-6
pubmed: 21257306
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Cancer Treat Res. 1995;75:95-112
pubmed: 7640169
J Natl Cancer Inst. 2016 May 12;108(8):
pubmed: 27172903
J Clin Oncol. 2007 Oct 10;25(29):4569-74
pubmed: 17876008
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Clin Cancer Res. 2017 Aug 15;23(16):4753-4760
pubmed: 28446505
Br J Cancer. 2013 Sep 17;109(6):1618-24
pubmed: 23963148
Nat Rev Clin Oncol. 2011 Oct 18;9(2):119-23
pubmed: 22009076
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
J Clin Oncol. 2013 Oct 10;31(29):3664-72
pubmed: 24019539
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Ann Surg Oncol. 2018 Jun;25(6):1454-1455
pubmed: 29616422
JAMA Oncol. 2015 Aug;1(5):653-61
pubmed: 26181352
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
J Natl Cancer Inst. 2014 Oct 29;106(12):
pubmed: 25359867
World J Gastroenterol. 2016 Jan 14;22(2):557-66
pubmed: 26811607
Nature. 2002 Aug 29;418(6901):934
pubmed: 12198537
Mol Cancer Res. 2018 Mar;16(3):476-485
pubmed: 29187560
JAMA. 2012 Apr 4;307(13):1383-93
pubmed: 22474202